Arena Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Arena Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Arena Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Arena Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Narcolepsy With or Without Cataplexy, with 1 trials.
Top-decile sponsor footprint
Arena Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
NCT04655599
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
NCT03996369
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT04162769
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
NCT04043455
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03945188
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
NCT03155932
Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
NCT03155945
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT02536404
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
NCT02447302
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
NCT02044874
Single-dose Safety Study of APD916 in Healthy Volunteers
NCT01093508
Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia
NCT00664664
A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
NCT00619931
Single-Dose Safety Study of APD791 in Healthy Volunteers
NCT00529646
Safety and Efficacy Study of APD125 in Patient With Insomnia
NCT00452179
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 2 |
Therapeutic Areas
How the Arena Pharmaceuticals early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 12 completed (80%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Narcolepsy With or Without Cataplexy (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Arena Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Arena Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
- Ascentage Pharma Group · 15 trials · 53% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Arena Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Arena Pharmaceuticals or any single study.
- None of Arena Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Narcolepsy With or Without Cataplexy is the condition Arena Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Narcolepsy With or Without Cataplexy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Arena Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.